In addition, defendants also failed to disclose that the growth of Otezla sales had dramatically slowed during Celgene's third fiscal quarter of 2017 and that the clinical and nonclinical pharmacology data in Celgene's new drug application ("NDA") for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene regarding the NDA. As a result of these false statements and/or omissions, the price of Celgene stock was artificially inflated between September 12, 2016 and February 27, 2018 to over $145 per share. On December 10, 2018 an amended complaint was filed and on February 8, 2019, the defendants filed a motion to dismiss the amended complaint. On February 27, 2019, a second amended complaint was filed and the defendants filed a motion to dismiss the second amended complaint. On December 19, 2019, the court issued an order granting in part and denying in part defendants' motion to dismiss.